Diabetes
Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.
Diabetes
Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, BMI, or baseline HbA1c.
Bladder Cancer
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
Diabetes
Bladder cancer risk increases with longer duration of use.
Bladder Cancer
Duration- and dose-response associations for pioglitazone; no correlation for rosiglitazone.
Bladder Cancer
But research reveals association with pancreatic and prostate cancer.
Slideshow
This slideshow reviews drug information for OSENI™ (alogliptin/pioglitazone). Table of Contents Slide 3: Indication, Dosage & AdministrationSlide 6: Use in Specific PopulationsSlide 8: Clinical PharmacologySlide 11: Warnings & PrecautionsSlide 15: Clinical Safety & EfficacySlide 20: Drug Storage & Supply
Bladder Cancer
Emerging evidence links bladder cancer to pelvic radiation therapy, dietary factors, and gene-environment interactions.
Drug Monograph
Alogliptin, pioglitazone; 12.5mg/15mg, 12.5mg/30mg, 12.5mg/45mg, 25mg/15mg, 25mg/30mg, 25mg/45mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
Diabetes
The AHA released a statement focusing on the importance of managing cardiovascular risk factors in patients with type 2 diabetes.
